On non-small cell lung cancer stage Ⅲ concurrent chemotherapy tumor markers before and after the clinical significance.docVIP

 PAGE \* MERGEFORMAT 14 On non-small cell lung cancer stage Ⅲ concurrent chemotherapy tumor markers before and after the clinical significance Of: Wu Wei Bai Xuelian Zhu Yun Wang Shubin [Abstract] Objective To detect non-small cell lung cancer stage Ⅲ (NSCLC) in a single agent paclitaxel plus concurrent radiotherapy before and after the tumor markers CEA, CA125, CYFRA21-1 levels, and to explore locally advanced (Ⅲ period before and after concurrent chemoradiotherapy for NSCLC in more than kinds of tumor markers of clinical significance, looking for NSCLC diagnosis, curative effect and prognosis of specific targets for prevention and treatment of NSCLC to provide a scientific basis. Methods initial treatment of locally advanced NSCLC 60 patients were randomly divided into two groups of 30 cases in each group for the treatment group and the other was the control group, treatment group with three dimensional conformal radiotherapy (3D-CRT with concurrent single-agent paclitaxel (40mg/m2) weekly chemotherapy in the control group were simply 3D-CRT. collected two weeks before treatment and after treatment, CT images of patients and serum CEA, CA125 and CYFRA21-1 levels, through SPSS13.0 software for statistical analysis. Results 1. the efficacy of the treatment group than the control group The difference was statistically significant (P lt;0.05); 2. In both groups, efficacy evaluation for the CR, PR patients, two months after the treatment serum CEA, CA125 and CYFRA21-1 levels significantly decreased than that before treatment (P lt;0.05), efficacy evaluation of patients with PD after treatment CEA, CA125 and CYFRA21-1 levels than before treatment had increased significantly (P lt;0.05) .3. tumor marker levels and efficacy was positively correlation (P lt;0.05). Conclusion Serum CEA, CYFRA2I-1, CA125 can be used for joint detection for the diagnosis of advanced NSCLC, the efficacy and prognosis of good clinical value. locally advanced NSCLC patients, single agen